EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 434 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR One Year in Cancer Research and Much to Celebrate December 20, 2024 Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to... January 20, 2021 Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... September 2, 2020 Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 Load more HOT NEWS FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... El cáncer en mi comunidad: Cómo superar las desigualdades en la... Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC... ¿Qué es la escasez de medicamentos y cómo puede afectar a...
